OBJECTIVE: To probe into the effects off doxofylline combined with bidirectional positive airway pressure（BiPAP） on inflammatory factors

lipocalin-1（LCN1） and hypoxia-inducible factor-1α（HIF-1α） in elderly patients with chronic obstructive pulmonary disease（COPD）. METHODS: This was a prospective study

totally 80 elderly patients with COPD diagnosed and treated in this hospital from 2019 to 2020 were study subjects

which were extracted to be divided into observation group and control group via the random number table

with 40 cases in each group. Patients in both groups were treated with doxorubicin for 4 weeks

and the observation group was given BiPAP on this basis. Differences in therapeutic effects

pulmonary function

inflammatory indicators

serum LCN1 and HIF-1α levels

as well as the incidences of adverse drug reactions were compared between two groups. RESULTS: In terms of total effective rate

the control group was 75.00%（30/40）

while in comparison

the observation group had a higher total effective rate of 92.50%（37/40）

with statistically significant difference between two groups（U=2.152

P=0.032）. After treatment

the forced vital capacity（FVC）

forced expiratory volume in one second（FEV

1

） and forced expiratory volume in one second percentage（FEV

1

%） of both groups were significantly higher than before treatment

and the FVC（t=2.858

P=0.005）

FEV

1

（t=2.957

P=0.004） and FEV

1

%（t=8.065

P=0.000） in the observation group were significantly higher than the control group

with statistically significant differences. After treatment

the interleukin（IL） 1β

tumor necrosis factor α（TNF-α） and IL-6 levels of both groups were significantly lower than before treatment

and the IL-1β（t=13.457

P=0.000）

TNF-α（t=2.977

P=0.004） and IL-6（t=2.002

P=0.049） in the observation group were significantly lower than the control group

with statistically significant differences. Compared with before treatment

the LCN1 was significantly higher and HIF-1α was significantly lower in both groups; LCN1（t=2.903

P=0.005） was significantly higher and HIF-1α（t=88.588

P=0.000） was significantly lower in the observation group than the control group

with statistically significant differences. The differences in incidences of adverse drug reactions such as fever

palpitations

rash

diarrhea and nausea between the two groups were not statistically significant（P

>

0.05）. CONCLUSIONS: Elderly patients with CODP treated with doxorubicin combined with BiPAP has significant increase in LCN1

significant decrease in HIF-1α

and significant relief in inflammatory response

with remarkable effects.